Neurocrine Biosciences Sees 89% Rapid Symptom Improvement and 96% Functional Gains with INGREZZA
NBIX•Clinician-reported data show that 89% of individuals with intellectual and developmental disabilities and tardive dyskinesia treated with INGREZZA experienced symptom improvement within four weeks. Following treatment, 96% of those with baseline functional impairments saw gains in overall functional status and improvements in emotions, socializing, dexterity and speech.
1. Data Highlights
In a clinician-reported analysis of 30 individuals with intellectual and developmental disabilities and tardive dyskinesia who initiated INGREZZA between January and June 2024, 89% experienced reductions in TD symptom severity within four weeks. Among those with impairments at baseline, 96% showed improvement in overall functional status following treatment.
2. Patient Subgroup Details
The subgroup had a mean age of 47.3 years (SD 14.6) and included 70% with schizophrenia and 17% with mood disorders. At baseline, 70% of patients exhibited moderate to severe TD movement severity, and 90% reported negative impacts on daily independence and functional status.
3. Functional and Socio-emotional Improvements
Clinicians reported broad functional gains post-INGREZZA: independence improved in 83% of impaired patients, emotions in 85%, socializing with family and friends in 92%, dexterity in 91% and speech in 100%. These outcomes underscore improvements beyond motor symptoms, including socio-emotional well-being and communication skills.
4. Potential Commercial Implications
These positive outcomes in a historically underrepresented population could support label expansion and strengthen INGREZZA’s market positioning for treating Tardive Dyskinesia in patients with intellectual and developmental disabilities, addressing a significant unmet need.
